Checkmate Pharmaceuticals Liabilities 2024

Checkmate Pharmaceuticals Aktienanalyse

What does Checkmate Pharmaceuticals do?

Checkmate Pharmaceuticals Inc is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2015 and specializes in the research and development of immuno-oncology therapies. The company has an innovative business model aimed at improving the immune response against cancer. It utilizes the natural ability of the immune system to recognize and eliminate cancer cells. Immuno-oncology is a major trend in cancer therapy today, with the goal of harnessing the body's own immune system to fight cancer cells. Checkmate Pharmaceuticals focuses on the development of unique first-in-class immunotherapeutics. The company collaborates closely with leading academic institutions and international organizations to maximize the potential of its technology and achieve the best results. The business of Checkmate Pharmaceuticals can be divided into three areas, from the Checkmate platform technology, for which multiple patents have been filed, to the two products: CMP-001 (classified as Breakthrough Therapy) and CMP-003. The Checkmate platform technology is based on stimulating immune responses through the ligation of oligonucleotides, which in turn is intended to promote the recognition and elimination of cancer cells. This method aims to safely and effectively harness the benefits of immunotherapy and successfully control the potential hazards of the immune system. CMP-001 is an immunotherapeutic currently in phase 2a clinical development. It is a combination of an adjuvant called STING agonists (also known as Sting-Signalling agonist) and a toll-like receptor-ligand of nucleotide (TLR-9), which help stimulate the body's immune system and trigger an immune response against cancer cells. CMP-001 has been granted 'Breakthrough Therapy' status by the US FDA, meaning that the drug offers a significant advancement in the treatment of patients with serious or life-threatening diseases compared to currently available therapies. CMP-003 is another development by Checkmate Pharmaceuticals, aiming to regulate excessive immune response. Along with STING, antibodies against poxviruses have been shown to activate the immune system and enable effective tumor therapy. One of the main target populations for Checkmate Pharmaceuticals is patients with various types of tumors such as melanoma, small cell lung cancer, and solid tumors that respond to immune system stimulation. Currently, the company is financed by renowned capital investors such as F-Prime Capital, HBM Healthcare Investments, and Sofinnova Investments. The company offers promising perspectives in cancer research and has the potential to deliver further advancements in the field of immuno-oncology with new products. These developments can help make cancer therapy more effective and safer, ultimately moving towards the goal of fighting cancer. Checkmate Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Checkmate Pharmaceuticals's Liabilities

Checkmate Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Checkmate Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Checkmate Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Checkmate Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Checkmate Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Checkmate Pharmaceuticals stock

What is the level of liabilities of Checkmate Pharmaceuticals this year?

Checkmate Pharmaceuticals has a debt balance of 9.38 M USD this year.

What were the liabilities of Checkmate Pharmaceuticals compared to the previous year?

The liabilities of Checkmate Pharmaceuticals have increased by 0% dropped compared to the previous year.

What are the consequences of high debt for investors of Checkmate Pharmaceuticals?

High liabilities can pose a risk for investors of Checkmate Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Checkmate Pharmaceuticals?

Low liabilities mean that Checkmate Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Checkmate Pharmaceuticals affect the company?

An increase in liabilities of Checkmate Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Checkmate Pharmaceuticals affect the company?

A decrease in the liabilities of Checkmate Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Checkmate Pharmaceuticals?

Some factors that can influence the liabilities of Checkmate Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Checkmate Pharmaceuticals so important for investors?

The liabilities of Checkmate Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Checkmate Pharmaceuticals take to modify the liabilities?

To change its liabilities, Checkmate Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Checkmate Pharmaceuticals pay?

Over the past 12 months, Checkmate Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Checkmate Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Checkmate Pharmaceuticals?

The current dividend yield of Checkmate Pharmaceuticals is .

When does Checkmate Pharmaceuticals pay dividends?

Checkmate Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Checkmate Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Checkmate Pharmaceuticals located?

Checkmate Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Checkmate Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Checkmate Pharmaceuticals from 11/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Checkmate Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/18/2024.

What was the dividend of Checkmate Pharmaceuticals in the year 2023?

In the year 2023, Checkmate Pharmaceuticals distributed 0 USD as dividends.

In which currency does Checkmate Pharmaceuticals pay out the dividend?

The dividends of Checkmate Pharmaceuticals are distributed in USD.